Antibody-Drug Conjugates Used in Breast Cancers

被引：8
作者：
Abbas, Aram J. [1 ]
Ibrahim, Marah F. [2 ]
Saifo, Maher S. [1 ,2 ]
机构：
[1] Damascus Univ, Fac Med, Damascus, Syria
[2] Alsham Private Univ, Fac Pharm, Damascus, Syria
来源：
JOURNAL OF ONCOLOGY | 2021年 / 2021卷
关键词：
SACITUZUMAB GOVITECAN; MONOCLONAL-ANTIBODY; NEXT-GENERATION; CHALLENGES; STRATEGIES; SELECTION; ISOTYPE; DESIGN; LINKER; ADCS;
D O I：
10.1155/2021/9927433
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The prognosis of breast cancer has radically changed in recent years and continues to improve due to the broad application of effective therapies. New targeting strategies including targeted delivery of cytotoxic drugs via receptor-targeting agents have been developed. We summarize recent publications and developments of novel antibody-drug conjugates (ADCs) used to control breast cancer.
引用
收藏
页数：7
相关论文
共 60 条
  • [1] [Anonymous], 2020, ADC REV
  • [2] [Anonymous], 2020, A R J O A D MI130004
  • [3] [Anonymous], 2020, CONJUGATES A R J O A
  • [4] MI130004, a Novel Antibody-Drug Conjugate Combining Trastuzumab with a Molecule of Marine Origin, Shows Outstanding In Vivo Activity against HER2-Expressing Tumors
    Aviles, Pablo
    Manuel Dominguez, Juan
    Jose Guillen, Maria
    Jose Munoz-Alonso, Maria
    Mateo, Cristina
    Rodriguez-Acebes, Raquel
    Manuel Molina-Guijarro, Jose
    Francesch, Andres
    Fernando Martinez-Leal, Juan
    Munt, Simon
    Galmarini, Carlos M.
    Cuevas, Carmen
    [J]. MOLECULAR CANCER THERAPEUTICS, 2018, 17 (04) : 786 - 794
  • [5] Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
    Bardia, A.
    Mayer, I. A.
    Vahdat, L. T.
    Tolaney, S. M.
    Isakoff, S. J.
    Diamond, J. R.
    O'Shaughnessy, J.
    Moroose, R. L.
    Santin, A. D.
    Abramson, V. G.
    Shah, N. C.
    Rugo, H. S.
    Goldenberg, D. M.
    Sweidan, A. M.
    Iannone, R.
    Washkowitz, S.
    Sharkey, R. M.
    Wegener, W. A.
    Kalinsky, K.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (08) : 741 - 751
  • [6] Ror2 Signaling and Its Relevance in Breast Cancer Progression
    Bayerlova, Michaela
    Menck, Kerstin
    Klemm, Florian
    Wolff, Alexander
    Pukrop, Tobias
    Binder, Claudia
    Beissbarth, Tim
    Bleckmann, Annalen
    [J]. FRONTIERS IN ONCOLOGY, 2017, 7
  • [7] Strategies and challenges for the next generation of antibody drug conjugates
    Beck, Alain
    Goetsch, Liliane
    Dumontet, Charles
    Corvaia, Nathalie
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2017, 16 (05) : 315 - 337
  • [8] Strategies and challenges for the next generation of therapeutic antibodies
    Beck, Alain
    Wurch, Thierry
    Bailly, Christian
    Corvaia, Nathalie
    [J]. NATURE REVIEWS IMMUNOLOGY, 2010, 10 (05) : 345 - 352
  • [9] Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs
    Behrens, Christopher R.
    Ha, Edward H.
    Chinn, Lawrence L.
    Bowers, Simeon
    Probst, Gary
    Fitch-Bruhns, Maureen
    Monteon, Jorge
    Valdiosera, Amanda
    Bermudez, Abel
    Liao-Chan, Sindy
    Wong, Tiffany
    Melnick, Jonathan
    Theunissen, Jan-Willem
    Flory, Mark R.
    Houser, Derrick
    Venstrom, Kristy
    Levashova, Zoia
    Sauer, Paul
    Migone, Thi-Sau
    van der Horst, Edward H.
    Halcomb, Randall L.
    Jackson, David Y.
    [J]. MOLECULAR PHARMACEUTICS, 2015, 12 (11) : 3986 - 3998
  • [10] Targeted cancer therapy: Conferring specificity to cytotoxic drugs
    Chari, Ravi V. J.
    [J]. ACCOUNTS OF CHEMICAL RESEARCH, 2008, 41 (01) : 98 - 107
123456